Open Access
Frontiers in Public Health, volume 7
The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
Karaiskos Ilias
1
,
Lagou Styliani
2
,
Pontikis Konstantinos
3
,
Rapti Vasiliki
2
,
Poulakou Garyphallia
2
1
First Department of Internal Medicine-Infectious Diseases, Hygeia General Hospital, Greece
|
2
Third Department of Medicine, School of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Greece
|
3
ICU First Department of Respiratory Medicine, School of Medicine, Sotiria General Hospital, National and Kapodistrian University of Athens, Greece
|
Publication type: Journal Article
Publication date: 2019-06-11
Journal:
Frontiers in Public Health
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor: 5.2
ISSN: 22962565
PubMed ID:
31245348
Public Health, Environmental and Occupational Health
Abstract
The recent expansion of multidrug resistant and pan-drug-resistant pathogens poses significant challenges in the treatment of healthcare associated infections. An important advancement, is a handful of recently launched new antibiotics targeting some of the current most problematic Gram-negative pathogens, namely Carbapenem -producing Enterobacteriaceae (CRE) and Carbapenem-resistant P. aeruginosa (CRPA). Less options are available against carbapenem-resistant Acinetobacter baumannii (CRAB) and strains producing metallo-beta lactamases (MBL). Ceftazidime-avibactam signalled a turning point in the treatment of KPC and partly OXA- type carbapenemases, whereas meropenem-vaborbactam was added as a potent combination against KPC-producers. Ceftolozane-tazobactam could be seen as an ideal beta-lactam backbone for the treatment of CRPA. Plazomicin, an aminoglycoside with better pharmacokinetics and less toxicity compared to other class members, will cover important proportions of multi-drug resistant pathogens. Eravacycline holds promise in the treatment of infections by CRAB, with a broad spectrum of activity similar to tigecycline and improved pharmacokinetics. Novel drugs and combinations are not to be considered “panacea” for the ongoing crisis in the therapy of XDR Gram-negative bacteria and colistin will continue to be considered as a fundamental companion drug for the treatment of carbapenem-resistant Enterobacteriaceae (particularly in areas where MBL predominate), for the treatment of CRPA (in many cases being the only in vitro active drug) as well as CRAB. Aminoglycosides are still important companion antibiotics. Finally, fosfomycin as part of combination treatment for CRE infections and P. aeruginosa, deserves a greater attention. Optimal conditions for monotherapy and the “when and how” of combination treatments integrating the novel agents will be discussed.
Citations by journals
|
5
10
15
20
25
|
|
|
Antibiotics
|
Antibiotics
24 publications, 13.87%
|
|
International Journal of Antimicrobial Agents
|
International Journal of Antimicrobial Agents
10 publications, 5.78%
|
|
Infection and Drug Resistance
|
Infection and Drug Resistance
8 publications, 4.62%
|
|
Journal of Antimicrobial Chemotherapy
|
Journal of Antimicrobial Chemotherapy
8 publications, 4.62%
|
|
Current Opinion in Infectious Diseases
|
Current Opinion in Infectious Diseases
5 publications, 2.89%
|
|
Microorganisms
|
Microorganisms
5 publications, 2.89%
|
|
Pathogens
|
Pathogens
5 publications, 2.89%
|
|
Pharmaceuticals
|
Pharmaceuticals
4 publications, 2.31%
|
|
Expert Review of Anti-Infective Therapy
|
Expert Review of Anti-Infective Therapy
4 publications, 2.31%
|
|
Biomedicines
|
Biomedicines
3 publications, 1.73%
|
|
Future Microbiology
|
Future Microbiology
3 publications, 1.73%
|
|
Frontiers in Microbiology
|
Frontiers in Microbiology
3 publications, 1.73%
|
|
Journal of Microbiology, Immunology and Infection
|
Journal of Microbiology, Immunology and Infection
3 publications, 1.73%
|
|
ACS Infectious Diseases
|
ACS Infectious Diseases
3 publications, 1.73%
|
|
Journal of Chemotherapy
|
Journal of Chemotherapy
3 publications, 1.73%
|
|
F1000Research
|
F1000Research
2 publications, 1.16%
|
|
Microbial Drug Resistance
|
Microbial Drug Resistance
2 publications, 1.16%
|
|
Life
|
Life
2 publications, 1.16%
|
|
International Journal of Molecular Sciences
|
International Journal of Molecular Sciences
2 publications, 1.16%
|
|
Frontiers in Cellular and Infection Microbiology
|
Frontiers in Cellular and Infection Microbiology
2 publications, 1.16%
|
|
Infectious Diseases and Therapy
|
Infectious Diseases and Therapy
2 publications, 1.16%
|
|
BMC Infectious Diseases
|
BMC Infectious Diseases
2 publications, 1.16%
|
|
Expert Opinion on Pharmacotherapy
|
Expert Opinion on Pharmacotherapy
2 publications, 1.16%
|
|
JAC-Antimicrobial Resistance
|
JAC-Antimicrobial Resistance
2 publications, 1.16%
|
|
Pharmacological Reviews
|
Pharmacological Reviews
1 publication, 0.58%
|
|
Surgical Infections
|
Surgical Infections
1 publication, 0.58%
|
|
Journal of Medical Microbiology
|
Journal of Medical Microbiology
1 publication, 0.58%
|
|
Emerging Topics in Life Sciences
|
Emerging Topics in Life Sciences
1 publication, 0.58%
|
|
Journal of International Medical Research
|
Journal of International Medical Research
1 publication, 0.58%
|
|
5
10
15
20
25
|
Citations by publishers
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
49 publications, 28.32%
|
|
Elsevier
|
Elsevier
28 publications, 16.18%
|
|
Springer Nature
|
Springer Nature
12 publications, 6.94%
|
|
Taylor & Francis
|
Taylor & Francis
11 publications, 6.36%
|
|
Oxford University Press
|
Oxford University Press
10 publications, 5.78%
|
|
Dove Medical Press
|
Dove Medical Press
8 publications, 4.62%
|
|
Wolters Kluwer Health
|
Wolters Kluwer Health
8 publications, 4.62%
|
|
Frontiers Media S.A.
|
Frontiers Media S.A.
8 publications, 4.62%
|
|
American Chemical Society (ACS)
|
American Chemical Society (ACS)
6 publications, 3.47%
|
|
Future Medicine
|
Future Medicine
3 publications, 1.73%
|
|
Mary Ann Liebert
|
Mary Ann Liebert
3 publications, 1.73%
|
|
F1000 Research
|
F1000 Research
2 publications, 1.16%
|
|
SAGE
|
SAGE
2 publications, 1.16%
|
|
Wiley
|
Wiley
2 publications, 1.16%
|
|
Royal Society of Chemistry (RSC)
|
Royal Society of Chemistry (RSC)
2 publications, 1.16%
|
|
American Society for Pharmacology and Experimental Therapeutics
|
American Society for Pharmacology and Experimental Therapeutics
1 publication, 0.58%
|
|
Microbiology Society
|
Microbiology Society
1 publication, 0.58%
|
|
Portland Press
|
Portland Press
1 publication, 0.58%
|
|
BMJ
|
BMJ
1 publication, 0.58%
|
|
American Society for Microbiology
|
American Society for Microbiology
1 publication, 0.58%
|
|
European Journal of Chemistry
|
European Journal of Chemistry, 1, 0.58%
European Journal of Chemistry
1 publication, 0.58%
|
|
Russian Periodontal Association (RPA)
|
Russian Periodontal Association (RPA)
1 publication, 0.58%
|
|
Saint-Petersbug State University of Veterinary Medicine
|
Saint-Petersbug State University of Veterinary Medicine
1 publication, 0.58%
|
|
AME Publishing Company
|
AME Publishing Company
1 publication, 0.58%
|
|
5
10
15
20
25
30
35
40
45
50
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2019,2020,2021,2022,2023,2024],"ids":[0,0,0,0,0,0],"codes":[0,0,0,0,0,0],"imageUrls":["","","","","",""],"datasets":[{"label":"Citations number","data":[4,40,45,43,30,11],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":["2.31","23.12","26.01","24.86","17.34","6.36"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Antibiotics","International Journal of Antimicrobial Agents","Infection and Drug Resistance","Journal of Antimicrobial Chemotherapy","Current Opinion in Infectious Diseases","Microorganisms","Pathogens","Pharmaceuticals","Expert Review of Anti-Infective Therapy","Biomedicines","Future Microbiology","Frontiers in Microbiology","Journal of Microbiology, Immunology and Infection","ACS Infectious Diseases","Journal of Chemotherapy","F1000Research","Microbial Drug Resistance","Life","International Journal of Molecular Sciences","Frontiers in Cellular and Infection Microbiology","Infectious Diseases and Therapy","BMC Infectious Diseases","Expert Opinion on Pharmacotherapy","JAC-Antimicrobial Resistance","Pharmacological Reviews","Surgical Infections","Journal of Medical Microbiology","Emerging Topics in Life Sciences","Journal of International Medical Research"],"ids":[1488,4680,12706,24706,1748,6197,20044,1203,14733,24421,341,24403,16432,7781,2030,24267,4802,23944,14627,21709,19665,24948,23046,29990,1747,5431,11167,26998,22431],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/WEXVM2IukNfkmwoqmPhtMKmAeERljKWAbbXmEX7m_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/s6JtNKPXrzklKtbQZ4HrtzuJT0P7eHPX9U8x0nss_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/RlMKyKHh4Q2iTSKF38VHwIFW4f6Ke5ChRSXbQHkq_medium.webp","\/storage\/images\/resized\/nUqNrP9GnM1t0BrAIXp1LBodjU8aIJ2Fk4pLfGhZ_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp"],"datasets":[{"label":"","data":[24,10,8,8,5,5,5,4,4,3,3,3,3,3,3,2,2,2,2,2,2,2,2,2,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[13.87,5.78,4.62,4.62,2.89,2.89,2.89,2.31,2.31,1.73,1.73,1.73,1.73,1.73,1.73,1.16,1.16,1.16,1.16,1.16,1.16,1.16,1.16,1.16,0.58,0.58,0.58,0.58,0.58],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Multidisciplinary Digital Publishing Institute (MDPI)","Elsevier","Springer Nature","Taylor & Francis","Oxford University Press","Dove Medical Press","Wolters Kluwer Health","Frontiers Media S.A.","American Chemical Society (ACS)","Future Medicine","Mary Ann Liebert","F1000 Research","SAGE","Wiley","Royal Society of Chemistry (RSC)","American Society for Pharmacology and Experimental Therapeutics","Microbiology Society","Portland Press","BMJ","American Society for Microbiology","European Journal of Chemistry","Russian Periodontal Association (RPA)","Saint-Petersbug State University of Veterinary Medicine","AME Publishing Company"],"ids":[202,17,8,18,19,417,32,208,40,6949,230,7910,31,11,123,695,827,801,6954,142,6979,9272,7901,1566],"codes":[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],"imageUrls":["\/storage\/images\/resized\/MjH1ITP7lMYGxeqUZfkt2BnVLgjkk413jwBV97XX_medium.webp","\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/5YZtvLvkPZuc2JHOaZsjCvGSHFCuC3drUwN3YAc5_medium.webp","\/storage\/images\/resized\/yNSijlgQghQF53VZuyFLA30CKDe4j3HK74Vtpnxa_medium.webp","\/storage\/images\/resized\/wVWp6zaxUsMdR03dYMdOZoesUrVGtNMWkHKByIvT_medium.webp","\/storage\/images\/resized\/6QE8LXWrLpkoy5A2te6hw7who46GeCoTYIstuoAz_medium.webp","\/storage\/images\/resized\/4QWA67eqfcfyOiA8Wk7YnqroHFqQbTsmDJUYTCTg_medium.webp","\/storage\/images\/resized\/iLiQsFqFaSEx6chlGQ5fbAwF6VYU3WWa08hkss0g_medium.webp","\/storage\/images\/resized\/AN2jnDN59NmKaS4CWLHAGstADL2DbnatQScsFA6C_medium.webp","\/storage\/images\/resized\/Zy5YST233rzRbZP24I24MzZm64hz20ZV9qQopmMn_medium.webp","\/storage\/images\/resized\/WEXVM2IukNfkmwoqmPhtMKmAeERljKWAbbXmEX7m_medium.webp","\/storage\/images\/resized\/ruydfaB80LDjlkYqsfOeUAZohOIODyq7bQzis5O7_medium.webp","\/storage\/images\/resized\/bRyGpdm98BkAUYiK1YFNpl5Z7hPu6Gd87gbIeuG3_medium.webp","\/storage\/images\/resized\/leiAYcRDGTSl5B1eCnwpSGqmDEUEfDPPoYisFGhT_medium.webp","\/storage\/images\/resized\/s6JtNKPXrzklKtbQZ4HrtzuJT0P7eHPX9U8x0nss_medium.webp","\/storage\/images\/resized\/RlMKyKHh4Q2iTSKF38VHwIFW4f6Ke5ChRSXbQHkq_medium.webp","\/storage\/images\/resized\/nUqNrP9GnM1t0BrAIXp1LBodjU8aIJ2Fk4pLfGhZ_medium.webp","\/storage\/images\/resized\/hysFKdIDQMKHPbF1uLxJ3M6dQA4gPVuC6ZeA7m5a_medium.webp","\/storage\/images\/resized\/VPE7q24PXoHr5SS2SqfEgxccSMUxWLfZINOX60uo_medium.webp","","\/storage\/images\/resized\/j6jgrhCRexVF8R7i1Xc2tGEXXEiRRyWy1HP2MB5Q_medium.webp","\/storage\/images\/resized\/h1ELD9xgWtfOjuQLPydRMZg7xrVfuRKfNeGr85PQ_medium.webp","\/storage\/images\/resized\/PYBAYQjpFdxPQPRGY3kU5Xzbu0W7K7umVNk0TY9i_medium.webp"],"datasets":[{"label":"","data":[49,28,12,11,10,8,8,8,6,3,3,2,2,2,2,1,1,1,1,1,1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[28.32,16.18,6.94,6.36,5.78,4.62,4.62,4.62,3.47,1.73,1.73,1.16,1.16,1.16,1.16,0.58,0.58,0.58,0.58,0.58,0.58,0.58,0.58,0.58],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Karaiskos I. et al. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How // Frontiers in Public Health. 2019. Vol. 7.
GOST all authors (up to 50)
Copy
Karaiskos I., Lagou S., Pontikis K., Rapti V., Poulakou G. The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How // Frontiers in Public Health. 2019. Vol. 7.
Cite this
RIS
Copy
TY - JOUR
DO - 10.3389/fpubh.2019.00151
UR - https://doi.org/10.3389%2Ffpubh.2019.00151
TI - The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
T2 - Frontiers in Public Health
AU - Karaiskos, Ilias
AU - Lagou, Styliani
AU - Pontikis, Konstantinos
AU - Rapti, Vasiliki
AU - Poulakou, Garyphallia
PY - 2019
DA - 2019/06/11 00:00:00
PB - Frontiers Media S.A.
VL - 7
PMID - 31245348
SN - 2296-2565
ER -
Cite this
BibTex
Copy
@article{2019_Karaiskos,
author = {Ilias Karaiskos and Styliani Lagou and Konstantinos Pontikis and Vasiliki Rapti and Garyphallia Poulakou},
title = {The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How},
journal = {Frontiers in Public Health},
year = {2019},
volume = {7},
publisher = {Frontiers Media S.A.},
month = {jun},
url = {https://doi.org/10.3389%2Ffpubh.2019.00151},
doi = {10.3389/fpubh.2019.00151}
}